

(19)



(11)

EP 2 146 732 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:

A61P 1/08 (2006.01)

(86) International application number:

PCT/US2008/004640

(48) Corrigendum issued on:

26.12.2012 Bulletin 2012/52

(87) International publication number:

WO 2008/124183 (16.10.2008 Gazette 2008/42)

(45) Date of publication and mention of the grant of the patent:

31.10.2012 Bulletin 2012/44

(21) Application number: **08742733.2**

(22) Date of filing: **10.04.2008**

(54) **METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES**

VERFAHREN ZUR BEHANDLUNG ODER PRÄVENTION VON ERBRECHEN MIT
 WACHSTUMSHORMON-SEKRETAGOGA

PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DE VOMISSEMENT METTANT EN UVRE
 DES SÉCRÉTAGOGUES D'HORMONES DE CROISSANCE

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
 RO SE SI SK TR**

**US-A1- 2007 021 331 US-A1- 2007 037 751
 US-B1- 6 303 620 US-B1- 6 919 315
 US-B2- 6 576 648**

(30) Priority: **10.04.2007 US 922742 P**

(43) Date of publication of application:

27.01.2010 Bulletin 2010/04

(73) Proprietor: **Helsinn Healthcare SA**

6912 Lugano-Pazzallo (CH)

(72) Inventors:

- **MANN, William, R.**
Sparta, NJ 07871 (US)
- **POLVINO, William, J.**
Tinton Falls, NJ 07724 (US)

- **LIU Y-L ET AL: "Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents." September 2006 (2006-09), CANCER CHEMOTHERAPY AND PHARMACOLOGY SEP 2006 LNKD- PUBMED:16435157, VOL. 58, NR. 3, PAGE(S) 326 - 333 , XP19423295 ISSN: 0344-5704**
* See abstract: ghrelin (a growth hormone secretagogue) alleviates dyspepsia (which includes vomiting) associated with chemotherapy *
- **RUDD JOHN A ET AL: "Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin." 9 January 2006 (2006-01-09), NEUROSCIENCE LETTERS 9 JAN 2006 LNKD- PUBMED:16182445, VOL. 392, NR. 1-2, PAGE(S) 79 - 83 , XP25024067 ISSN: 0304-3940** * See abstract: ghrelin, which is a growth hormone secretagogue provides a novel approach in the treatment of emesis *

(74) Representative: **Zardi, Marco et al**

M. Zardi & Co. S.A.
Via Pioda 6
6900 Lugano (CH)

(56) References cited:

WO-A1-01/34593 US-A1- 2005 277 677

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 146 732 B8

- PAUL, BERNHARD J. ET AL: "A Practical Synthesis of the Pseudotripeptide RC - 1291" ORGANIC PROCESS RESEARCH & DEVELOPMENT , 10(2), 339-345 CODEN: OPRDFK; ISSN: 1083-6160, 2006, XP002590175
- YANG L ET AL: "1-[2(R)-(2-amino-2-methylpropionylamino)- 3-(1H-indol-3-yl) propionyl]- 3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and short-duration growth hormone secretagogue." 2 July 1998 (1998-07-02), JOURNAL OF MEDICINAL CHEMISTRY 2 JUL 1998 LNKD- PUBMED:9651148, VOL. 41, NR. 14, PAGE(S) 2439 - 2441 , XP002590176 ISSN: 0022-2623 * See preparation of L 163,540 a compound structurally related to RC-1291, and its activity as growth hormone secretagogue *